Iain R. Macpherson

7.1k total citations · 1 hit paper
82 papers, 2.4k citations indexed

About

Iain R. Macpherson is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Iain R. Macpherson has authored 82 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 18 papers in Cancer Research. Recurrent topics in Iain R. Macpherson's work include HER2/EGFR in Cancer Research (16 papers), Cancer Treatment and Pharmacology (15 papers) and Advanced Breast Cancer Therapies (14 papers). Iain R. Macpherson is often cited by papers focused on HER2/EGFR in Cancer Research (16 papers), Cancer Treatment and Pharmacology (15 papers) and Advanced Breast Cancer Therapies (14 papers). Iain R. Macpherson collaborates with scholars based in United Kingdom, United States and Canada. Iain R. Macpherson's co-authors include Valerie G. Brunton, Margaret C. Frame, Jim C. Norman, Paul Timpson, Colin Nixon, Christian Rolfo, Udai Banerji, Simon Lord, Valentina Boni and Jill J.J. Geenen and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and The Journal of Cell Biology.

In The Last Decade

Iain R. Macpherson

80 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study

2019 400 citations Iain R. Macpherson et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Iain R. Macpherson United Kingdom	21	1.1k	823	603	449	417	82	2.4k
Stephanie Hehlgans Germany	29	735 0.7×	1.1k 1.4×	338 0.6×	291 0.6×	450 1.1×	62	2.3k
Yoshinori Ino Japan	34	1.3k 1.2×	1.7k 2.1×	517 0.9×	363 0.8×	514 1.2×	63	3.5k
Kyle D. Holen United States	31	1.8k 1.7×	1.1k 1.4×	372 0.6×	479 1.1×	312 0.7×	126	3.2k
Aasmund Berner Norway	33	960 0.9×	1.2k 1.5×	582 1.0×	873 1.9×	278 0.7×	99	3.3k
Anne Hansen Ree Norway	30	1.3k 1.2×	1.2k 1.4×	661 1.1×	506 1.1×	132 0.3×	139	3.2k
Sarah P. Blagden United Kingdom	34	1.1k 1.0×	1.8k 2.2×	419 0.7×	366 0.8×	448 1.1×	154	3.2k
George S. Karagiannis United States	29	1.3k 1.2×	1.3k 1.6×	747 1.2×	374 0.8×	281 0.7×	72	3.3k
Darren R. Carpizo United States	27	1.4k 1.3×	1.5k 1.8×	715 1.2×	325 0.7×	157 0.4×	80	3.0k
Nicholas Papadopoulos United States	21	567 0.5×	1.7k 2.1×	454 0.8×	314 0.7×	205 0.5×	53	3.6k
Zhen‐Bin Ding China	36	1.3k 1.2×	1.9k 2.2×	1.1k 1.8×	481 1.1×	505 1.2×	89	4.1k

Countries citing papers authored by Iain R. Macpherson

Since Specialization

Citations

This map shows the geographic impact of Iain R. Macpherson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iain R. Macpherson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iain R. Macpherson more than expected).

Fields of papers citing papers by Iain R. Macpherson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iain R. Macpherson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iain R. Macpherson. The network helps show where Iain R. Macpherson may publish in the future.

Co-authorship network of co-authors of Iain R. Macpherson

This figure shows the co-authorship network connecting the top 25 collaborators of Iain R. Macpherson. A scholar is included among the top collaborators of Iain R. Macpherson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iain R. Macpherson. Iain R. Macpherson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cutts, Ros, Sarah Hrebien, Aditi Gulati, et al.. (2024). Discriminating subtypes in advanced breast cancer with ctDNA methylation profiling.. Journal of Clinical Oncology. 42(16_suppl). 1013–1013.

Kingston, Belinda, Alex Pearson, María Teresa Herrera-Abreu, et al.. (2023). ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1 -Mutant Breast Cancer. Cancer Discovery. 14(2). 274–289. 21 indexed citations

Winter, Matthew, Rob Coleman, Carlo Palmieri, et al.. (2022). A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results. Journal of bone oncology. 35. 100442–100442. 9 indexed citations

Rabas, Nicolas, Sarah E. Palmer, Louise Mitchell, et al.. (2021). PINK1 drives production of mtDNA-containing extracellular vesicles to promote invasiveness. The Journal of Cell Biology. 220(12). 90 indexed citations

Palmieri, Carlo & Iain R. Macpherson. (2021). A review of the evidence base for utilizing Child-Pugh criteria for guiding dosing of anticancer drugs in patients with cancer and liver impairment. ESMO Open. 6(3). 100162–100162. 7 indexed citations

Coleman, Rob, Janet E. Brown, Emma Rathbone, et al.. (2020). CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial. Trials. 21(1). 89–89. 11 indexed citations

Adamson, Philip D, Peter Hall, Ninian N. Lang, et al.. (2018). DYNAMIC CHANGES IN HIGH SENSITIVITY CARDIAC TROPONIN I IN RESPONSE TO ANTHRACYCLINE-BASED CHEMOTHERAPY: A PILOT STUDY FOR THE CARDIAC CARE TRIAL. Journal of the American College of Cardiology. 71(11). A701–A701. 1 indexed citations

Dornier, Emmanuel, Nicolas Rabas, Louise Mitchell, et al.. (2017). Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells. Nature Communications. 8(1). 2255–2255. 84 indexed citations

Cain, Henry, et al.. (2017). Neoadjuvant Therapy in Early Breast Cancer: Treatment Considerations and Common Debates in Practice. Clinical Oncology. 29(10). 642–652. 87 indexed citations

10.

Kristeleit, Hartmut, Marina Parton, Mark Beresford, et al.. (2016). Long-term Follow-up Data from Pivotal Studies of Adjuvant Trastuzumab in Early Breast Cancer. Targeted Oncology. 11(5). 579–591. 6 indexed citations

11.

Gill, Anthony J., et al.. (2014). Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma. European Journal of Cancer. 50(5). 944–952. 21 indexed citations

12.

Díaz‐Vera, Jésica, Yachuan Yu, Iain R. Macpherson, et al.. (2014). FAK Acts as a Suppressor of RTK-MAP Kinase Signalling in Drosophila melanogaster Epithelia and Human Cancer Cells. PLoS Genetics. 10(3). e1004262–e1004262. 10 indexed citations

13.

Macpherson, Iain R., Elena Rainero, Louise Mitchell, et al.. (2014). CLIC3 controls recycling of late endosomal MT1-MMP and dictates invasion and metastasis in breast cancer. Journal of Cell Science. 127(Pt 18). 3893–901. 83 indexed citations

14.

Yu, Xinzi, Tobias Zech, Laura McDonald, et al.. (2012). N-WASP coordinates the delivery and F-actin–mediated capture of MT1-MMP at invasive pseudopods. The Journal of Cell Biology. 199(3). 527–544. 138 indexed citations

15.

Macpherson, Iain R., Srinivasu Poondru, George R. Simon, et al.. (2012). A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours. European Journal of Cancer. 49(4). 782–789. 10 indexed citations

16.

Anthoney, Alan, Jay Naik, Iain R. Macpherson, et al.. (2012). Phase I study of TP300 in patients with advanced solid tumors with pharmacokinetic, pharmacogenetic and pharmacodynamic analyses. BMC Cancer. 12(1). 536–536. 8 indexed citations

17.

Macpherson, Iain R., et al.. (2010). Lure-and-kill as Reduced-risk Strategy for Managing Helicoverpa spp. on Conventional Cotton Crops within Transgenic Cotton Fields. Journal of Biological Control. 24(2). 91–103. 8 indexed citations

18.

Demetri, George D., Iain R. Macpherson, Ding Wang, et al.. (2009). Phase I Dose-Escalation and Pharmacokinetic Study of Dasatinib in Patients with Advanced Solid Tumors. Clinical Cancer Research. 15(19). 6232–6240. 126 indexed citations

19.

Macpherson, Iain R., Steven Hooper, Alan Serrels, et al.. (2007). p120-catenin is required for the collective invasion of squamous cell carcinoma cells via a phosphorylation-independent mechanism. Oncogene. 26(36). 5214–5228. 51 indexed citations

20.

Brunton, Valerie G., Iain R. Macpherson, & Margaret C. Frame. (2004). Cell adhesion receptors, tyrosine kinases and actin modulators: a complex three-way circuitry. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1692(2-3). 121–144. 149 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact